Search

Your search keyword '"Bonten, Marc J"' showing total 1,595 results
Start Over Author "Bonten, Marc J" Search Limiters Available in Library Collection
1,595 results on '"Bonten, Marc J"'

5. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)

Author

Serna, Almudena de la, Monteau, Sophie, Palomo, Virginia, Soriano, Elena, Gutierrez, David, Moreno, Elisa, Sojo-Dorado, Jesus, Morales, Isabel, Maldonado, Natalia, Santis, Lucia Valiente de, Ciezar, Antonio Plata, Ruiz Mesa, Juan Diego, Diaz, Beatriz Sobrino, Gomez, Ignacio Marquez, Camacho, Ines Perez, Cano, Angela, Frutos-Adame, Azahara, Guzman-Puche, Julia, Gracia-Ahufinger, Irene, Perez-Nadales, Elena, Torre-Gimenez, Julian, Pyrpasopoulou, Athina, Iosifidis, Elias, Chorafa, Elsa, Radovanovic, Ivana, Petrovic, Sladjana, Cvetkovi, Slavica, Melentijevic, Srdjan-Sanja, Bicmen, Can, Senol, Gunes, Tubau, Fe, Camara, Jordi, Daniel Gumucio, Victor, Bassoulis, Dimitris, Deliolanis, John, Pitiriga, Vassiliki Ch., Triarides, Nikolaos, Argiti, Efstathia, Legakis, Nikolaos J., Margarita, Kyriakidou, Gijón-Cordero, Desirée, Ruiz-Garbajosa, Patricia, Rossolini, Gian Maria, Nica, Maria, Talapan, Daniela, Medić, Deana, Prijić, Sanja Maričić, Caballero, Mireia Cantero, Ramírez, Lina M Parra, Bilgin, Hüseyin, Dalekos, George N., Stefos, Aggelos, Spyridis, Nikolaos, Michos, Athanasios, De Rosa, Francesco Giuseppe, Cavallo, Rossana, Petrosillo, Nicola, Dicaro, Antonio, Landini, Maria Paola, degli Atti, Marta Luisa Ciofi, Masanovic, Mileva, Matkovic, Dusan, Tsiodras, Sotirios, Blasi, Francesco, pasquale, Marta Di, Viscoli, Claudio, Vata, Andrei, Dorneanu, Olivia, Kapisyzi, Perlat, Vince, Adriana, Tsigou, Evdoxia, Maltezos, Efstratios, Komnos, Apostolos, Gogos, Charalampos, Franzetti, Fabio, Antonelli, Massimo, Lupse, Mihaela, Corneci, Dan, Tomescu, Dana, Georgescu, Anca, Bukarica, Ljiljana, Mitrović, Goran, Krstić, Nataša Lukić, Kurti, Arsim, Reuter, Sandra, Díaz-Pollán, Beatriz, Sabater, Julia Origüen, Muñoz, Patricia, Azap, Alpay, ancak, Banu, Sahin, Arife, Akalin, Halis, Paniagua-García, María, Bravo-Ferrer, Jose M., Pérez-Galera, Salvador, Kostyanev, Tomislav, de Kraker, Marlieke E.A., Feifel, Jan, Palacios-Baena, Zaira R., Schotsman, Joost, Cantón, Rafael, Daikos, George L., Carevic, Biljana, Dragovac, Gorana, Tan, Lionel K., Raka, Lul, Hristea, Adriana, Viale, Pierluigi, Akova, Murat, Cano, Ángela, Reguera, Jose María, Bartoloni, Alessandro, Florescu, Simin-Aysel, Benea, Serban, Asensio, Ángel, Korten, Volkan, Grundmann, Hajo, Goossens, Herman, Bonten, Marc J., Gutiérrez-Gutiérrez, Belén, and Rodríguez-Baño, Jesús

Published
2024
Full Text
View/download PDF

6. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

Author

de la Serna, Almudena, Monteau, Sophie, Palomo, Virginia, Soriano, Elena, Gutierrez, David, Moreno, Elisa, Palacios, Zaira, Morales, Isabel, Maldonado, Natalia, Ciezar, Antonio Plata, Ruiz Mesa, Juan Diego, Diaz, Beatriz Sobrino, Gomez, Ignacio Marquez, Camacho, Ines Perez, Frutos-Adame, Azahara, Guzman-Puche, Julia, Gracia-Ahufinger, Irene, Perez-Nadales, Elena, Torre-Gimenez, Julian, Pyrpasopoulou, Athina, Iosifidis, Elias, Chorafa, Elsa, Radovanovic, Ivana, Petrovic, Sladjana, Cvetkovi, Slavica, Melentijevic, Srdjan-Sanja, Bicmen, Can, Senol, Gunes, Tubau, Fe, Camara, Jordi, Gumucio, Victor Daniel, Bassoulis, Dimitris, Deliolanis, John, Pitiriga, Vassiliki Ch., Triarides, Nikolaos, Argiti, Efstathia, Legakis, Nikolaos J., Margarita, Kyriakidou, Gijón-Cordero, Desirée, Ruiz-Garbajosa, Patricia, Bartoloni, Alessandro, Rossolini, Gian Maria, Florescu, Simin-Aysel, Nica, Maria, Benea, Serban, Talapan, Daniela, Medić, Deana, Prijić, Sanja Maričić, Caballero, Mireia Cantero, Parra Ramírez, Lina M., Korten, Volkan, Bilgin, Hüseyin, Dalekos, George N., Stefos, Aggelos, Spyridis, Nikolaos, Michos, Athanasios, De Rosa, Francesco Giuseppe, Cavallo, Rossana, Petrosillo, Nicola, Dicaro, Antonio, Landini, Maria Paola, Ciofi degli Atti, Marta Luisa, Masanovic, Mileva, Matkovic, Dusan, Tsiodras, Sotirios, Blasi, Francesco, Di pasquale, Marta, Viscoli, Claudio, Vata, Andrei, Dorneanu, Olivia, Kapisyzi, Perlat, Vince, Adriana, Tsigou, Evdoxia, Maltezos, Efstratios, Komnos, Apostolos, Gogos, Charalampos, Franzetti, Fabio, Antonelli, Massimo, Lupse, Mihaela, Corneci, Dan, Tomescu, Dana, Georgescu, Anca, Bukarica, Ljiljana, Mitrović, Goran, Krstić, Nataša Lukić, Kurti, Arsim, Díaz-Pollán, Beatriz, Sabater, Julia Origüen, Muñoz, Patricia, Azap, Alpay, Sancak, Banu, Sahin, Arife, Akalin, Halis, Pérez-Galera, Salvador, Bravo-Ferrer, Jose M., Paniagua, María, Kostyanev, Tomislav, de Kraker, Marlieke E.A., Feifel, Jan, Sojo-Dorado, Jesús, Schotsman, Joost, Cantón, Rafael, Daikos, George L., Carevic, Biljana, Dragovac, Gorana, Tan, Lionel K., Raka, Lul, Hristea, Adriana, Viale, Pierluigi, Akova, Murat, Reguera, Jose María, Valiente de Santis, Lucía, Torre-Cisneros, Julián, Cano, Ángela, Roilides, Emmanuel, Radulovic, Lili, Kirakli, Cenk, Shaw, Evelyn, Falagas, Matthew E., Pintado, Vicente, Goossens, Herman, Bonten, Marc J., Gutiérrez-Gutiérrez, Belén, and Rodriguez-Baño, Jesús

Published
2023
Full Text
View/download PDF

8. The 2021 Dutch Working Party on Antibiotic Policy (SWAB) guidelines for empirical antibacterial therapy of sepsis in adults

Author

Sieswerda, Elske, Bax, Hannelore I., Hoogerwerf, Jacobien J., de Boer, Mark G. J., Boermeester, Marja, Bonten, Marc J. M., Dekker, Douwe, van Wijk, Roy Gerth, Juffermans, Nicole P., Kuindersma, Marnix, van der Linden, Paul D., Melles, Damian C., Pickkers, Peter, Schouten, Jeroen A., Rebel, Jasper R., van Zanten, Arthur R. H., Prins, Jan M., and Wiersinga, W. Joost

Published
2022
Full Text
View/download PDF

11. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)

Author

Julius Centrum, Ecraid, Epi Infectieziekten, Infection & Immunity, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectious Diseases, Paniagua-García, María, Bravo-Ferrer, Jose M, Pérez-Galera, Salvador, Kostyanev, Tomislav, de Kraker, Marlieke E A, Feifel, Jan, Palacios-Baena, Zaira R, Schotsman, Joost, Cantón, Rafael, Daikos, George L, Carevic, Biljana, Dragovac, Gorana, Tan, Lionel K, Raka, Lul, Hristea, Adriana, Viale, Pierluigi, Akova, Murat, Cano, Ángela, Reguera, Jose María, Bartoloni, Alessandro, Florescu, Simin-Aysel, Benea, Serban, Bukarica, Ljiljana, Asensio, Ángel, Korten, Volkan, Grundmann, Hajo, Goossens, Herman, Bonten, Marc J, Gutiérrez-Gutiérrez, Belén, Rodríguez-Baño, Jesús, COMBACTE-CARE-EURECA Team, Julius Centrum, Ecraid, Epi Infectieziekten, Infection & Immunity, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectious Diseases, Paniagua-García, María, Bravo-Ferrer, Jose M, Pérez-Galera, Salvador, Kostyanev, Tomislav, de Kraker, Marlieke E A, Feifel, Jan, Palacios-Baena, Zaira R, Schotsman, Joost, Cantón, Rafael, Daikos, George L, Carevic, Biljana, Dragovac, Gorana, Tan, Lionel K, Raka, Lul, Hristea, Adriana, Viale, Pierluigi, Akova, Murat, Cano, Ángela, Reguera, Jose María, Bartoloni, Alessandro, Florescu, Simin-Aysel, Benea, Serban, Bukarica, Ljiljana, Asensio, Ángel, Korten, Volkan, Grundmann, Hajo, Goossens, Herman, Bonten, Marc J, Gutiérrez-Gutiérrez, Belén, Rodríguez-Baño, Jesús, and COMBACTE-CARE-EURECA Team

Published
2024

12. Determinants of Systemic SARS-CoV-2-Specific Antibody Responses to Infection and to Vaccination: A Secondary Analysis of Randomised Controlled Trial Data

Author

Infection & Immunity, Epi Infectieziekten Team 1b, Epi Infectieziekten Team 1, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, Claus, Juana, Ten Doesschate, Thijs, Taks, Esther, Debisarun, Priya A, Smits, Gaby, van Binnendijk, Rob, van der Klis, Fiona, Verhagen, Lilly M, de Jonge, Marien I, Bonten, Marc J M, Netea, Mihai G, van de Wijgert, Janneke H H M, Infection & Immunity, Epi Infectieziekten Team 1b, Epi Infectieziekten Team 1, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, Claus, Juana, Ten Doesschate, Thijs, Taks, Esther, Debisarun, Priya A, Smits, Gaby, van Binnendijk, Rob, van der Klis, Fiona, Verhagen, Lilly M, de Jonge, Marien I, Bonten, Marc J M, Netea, Mihai G, and van de Wijgert, Janneke H H M

Published
2024

13. Glycan-specific IgM is critical for human immunity to Staphylococcus aureus

Author

MMB Research line 1, Infection & Immunity, Sepsis and Inflammation, Epi Infectieziekten Team 1, JC onderzoeksprogramma Infectious Diseases, Medische Staf Intensive Care, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, MMB Onderzoek en Onderwijs, Hendriks, Astrid, Kerkman, Priscilla F, Varkila, Meri R J, Haitsma Mulier, Jelle L G, Ali, Sara, Ten Doesschate, Thijs, van der Vaart, Thomas W, de Haas, Carla J C, Aerts, Piet C, Cremer, Olaf L, Bonten, Marc J M, Nizet, Victor, Liu, George Y, Codée, Jeroen D C, Rooijakkers, Suzan H M, van Strijp, Jos A G, van Sorge, Nina M, MMB Research line 1, Infection & Immunity, Sepsis and Inflammation, Epi Infectieziekten Team 1, JC onderzoeksprogramma Infectious Diseases, Medische Staf Intensive Care, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, MMB Onderzoek en Onderwijs, Hendriks, Astrid, Kerkman, Priscilla F, Varkila, Meri R J, Haitsma Mulier, Jelle L G, Ali, Sara, Ten Doesschate, Thijs, van der Vaart, Thomas W, de Haas, Carla J C, Aerts, Piet C, Cremer, Olaf L, Bonten, Marc J M, Nizet, Victor, Liu, George Y, Codée, Jeroen D C, Rooijakkers, Suzan H M, van Strijp, Jos A G, and van Sorge, Nina M

Published
2024

14. Acute kidney injury in Staphylococcus aureus bacteraemia: a recurrent events analysis

Author

Infection & Immunity, JC onderzoeksprogramma Infectious Diseases, Epi Infectieziekten Team 1, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, Buis, David T P, van der Vaart, Thomas W, Mohan, Asna, Prins, Jan M, van der Meer, Jan T M, Bonten, Marc J M, Jakulj, Lily, van Werkhoven, Cornelis H, Sigaloff, Kim C E, Infection & Immunity, JC onderzoeksprogramma Infectious Diseases, Epi Infectieziekten Team 1, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, Buis, David T P, van der Vaart, Thomas W, Mohan, Asna, Prins, Jan M, van der Meer, Jan T M, Bonten, Marc J M, Jakulj, Lily, van Werkhoven, Cornelis H, and Sigaloff, Kim C E

Published
2024

15. Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study

Author

Van Boven, Michiel, van Dorp, Christiaan H., Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A., Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J., Kretzschmar, Mirjam E., Bruijning-Verhagen, Patricia, Van Boven, Michiel, van Dorp, Christiaan H., Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A., Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J., Kretzschmar, Mirjam E., and Bruijning-Verhagen, Patricia

Abstract

Household studies provide an efficient means to study transmission of infectious diseases, enabling estimation of susceptibility and infectivity by person-type. A main inclusion criterion in such studies is usually the presence of an infected person. This precludes estimation of the hazards of pathogen introduction into the household. Here we estimate age- and time-dependent household introduction hazards together with within household transmission rates using data from a prospective household-based study in the Netherlands. A total of 307 households containing 1, 209 persons were included from August 2020 until March 2021. Follow-up of households took place between August 2020 and August 2021 with maximal follow-up per household mostly limited to 161 days. Almost 1 out of 5 households (59/307) had evidence of an introduction of SARS-CoV-2. We estimate introduction hazards and within-household transmission rates in our study population with penalized splines and stochastic epidemic models, respectively. The estimated hazard of introduction of SARS-CoV-2 in the households was lower for children (0-12 years) than for adults (relative hazard: 0.62; 95%CrI: 0.34-1.0). Estimated introduction hazards peaked in mid October 2020, mid December 2020, and mid April 2021, preceding peaks in hospital admissions by 1-2 weeks. Best fitting transmission models included increased infectivity of children relative to adults and adolescents, such that the estimated child-to-child transmission probability (0.62; 95%CrI: 0.40-0.81) was considerably higher than the adult-to-adult transmission probability (0.12; 95%CrI: 0.057-0.19). Scenario analyses indicate that vaccination of adults can strongly reduce household infection attack rates and that adding adolescent vaccination offers limited added benefit.

Published
2024

16. The Plasma Lipidomic Landscape in Patients with Sepsis due to Community-acquired Pneumonia

Author

Sepsis and Inflammation, Epi Infectieziekten, Infection & Immunity, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, Medische Staf Intensive Care, Chouchane, Osoul, Schuurman, Alex R, Reijnders, Tom D Y, Peters-Sengers, Hessel, Butler, Joe M, Uhel, Fabrice, Schultz, Marcus J, Bonten, Marc J, Cremer, Olaf L, Calfee, Carolyn S, Matthay, Michael A, Langley, Raymond J, Alipanah-Lechner, Narges, Kingsmore, Stephen F, Rogers, Angela, Weeghel, Michel van, Vaz, Frédéric M, van der Poll, Tom, Sepsis and Inflammation, Epi Infectieziekten, Infection & Immunity, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, Medische Staf Intensive Care, Chouchane, Osoul, Schuurman, Alex R, Reijnders, Tom D Y, Peters-Sengers, Hessel, Butler, Joe M, Uhel, Fabrice, Schultz, Marcus J, Bonten, Marc J, Cremer, Olaf L, Calfee, Carolyn S, Matthay, Michael A, Langley, Raymond J, Alipanah-Lechner, Narges, Kingsmore, Stephen F, Rogers, Angela, Weeghel, Michel van, Vaz, Frédéric M, and van der Poll, Tom

Published
2024

17. Examining pancreatic stone protein response in ICU-acquired bloodstream infections: a matched event analysis

Author

Infection & Immunity, Epi Infectieziekten Team 1, Medische Staf Intensive Care, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, Verlaan, Diede, Derde, Lennie P G, van der Poll, Tom, Bonten, Marc J M, Cremer, Olaf L, Infection & Immunity, Epi Infectieziekten Team 1, Medische Staf Intensive Care, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, Verlaan, Diede, Derde, Lennie P G, van der Poll, Tom, Bonten, Marc J M, and Cremer, Olaf L

Published
2024

18. Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study

Author

Epi Infectieziekten, Infection & Immunity, Epi Infectieziekten Team 1, Child Health, JC onderzoeksprogramma Methodologie, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Epi Infectieziekten Team 2, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, van Boven, Michiel, van Dorp, Christiaan H, Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A, Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J, Kretzschmar, Mirjam E, Bruijning-Verhagen, Patricia, Epi Infectieziekten, Infection & Immunity, Epi Infectieziekten Team 1, Child Health, JC onderzoeksprogramma Methodologie, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Epi Infectieziekten Team 2, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, van Boven, Michiel, van Dorp, Christiaan H, Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A, Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J, Kretzschmar, Mirjam E, and Bruijning-Verhagen, Patricia

Published
2024

19. The Utility of Risk Factors to Define Complicated Staphylococcus aureus Bacteremia in a Setting With Low Methicillin-Resistant S. aureus Prevalence

Author

Infection & Immunity, Epi Infectieziekten Team 1, JC onderzoeksprogramma Infectieziekten, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, van der Vaart, Thomas W, Prins, Jan M, Goorhuis, Abraham, Lemkes, Bregtje A, Sigaloff, Kim C E, Spoorenberg, Veroniek, Stijnis, Cornelis, Bonten, Marc J M, van der Meer, Jan T M, Infection & Immunity, Epi Infectieziekten Team 1, JC onderzoeksprogramma Infectieziekten, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, van der Vaart, Thomas W, Prins, Jan M, Goorhuis, Abraham, Lemkes, Bregtje A, Sigaloff, Kim C E, Spoorenberg, Veroniek, Stijnis, Cornelis, Bonten, Marc J M, and van der Meer, Jan T M

Published
2024

20. Biomarker guided antibiotic stewardship in community acquired pneumonia: A randomized controlled trial.

Author

Duijkers, Ruud, Prins, Hendrik J., Kross, Martijn, Snijders, Dominic, van den Berg, Jan W. K., Werkman, Gwendolyn M., van der Veen, Nynke, Schoorl, Marianne, Bonten, Marc J. M., van Werkhoven, Cornelis H., and Boersma, Wim G.

Subjects
COMMUNITY-acquired pneumonia, C-reactive protein, RANDOMIZED controlled trials, ANTIMICROBIAL stewardship, TEACHING hospitals
Abstract

Background: In community-acquired pneumonia (CAP), the role of biomarkers to shorten duration of antibiotic treatment has not been firmly established. We assessed the effectiveness of active feedback of treatment algorithms based on procalcitonin (PCT) and C-reactive protein (CRP), compared to standard care, on the duration of antibiotic treatment in patients hospitalized with community-acquired pneumonia (CAP) in non-ICU wards. Methods and findings: We performed a randomised, open label, parallel group, multi-centre trial in 3 Dutch teaching hospitals. Treatment was guided by a PCT algorithm, CRP algorithm or standard care. Participants were recruited by a member of the study team and randomised at day 2–3 of admission in a 1:1:1 ratio. Treatment was discontinued upon predefined thresholds of biomarkers that were assessed on admission, day 4 and days 5–7 if indicated. The primary outcome was total days on antibiotic treatment until day 30. In total 468 participants were included in this study. The median days on antibiotics (IQR) was 7 (IQR 7–10) in the control group, 4 (IQR 3–7) in the CRP group (rate ratio (RR) of 0.70, 95% CI 0.61–0.82 compared to standard care; p <0.001), and 5.5 (IQR 3–9) in the PCT group (RR of 0.78, 95% CI 0.68–0.89 compared to standard care; p <0.001). New antibiotics within the first 30 days were prescribed to 24, 23 and 35 patients in standard care, CRP and PCT groups, respectively. The hazard ratio for a new prescription in patients in the PCT group compared to standard care 1.63 (CI 0.97–2.75; p = 0.06). No difference in time to clinical stability or length of stay was found. Conclusions: A strategy of feedback of CRP-guided and PCT-guided treatment algorithms reduced the number of days on antibiotic in the first 30 days after hospital admission in non-ICU wards for CAP. The study was not powered to determine safety of shortening duration of antibiotic treatment. (NCT01964495). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Determinants of Systemic SARS-CoV-2-Specific Antibody Responses to Infection and to Vaccination: A Secondary Analysis of Randomised Controlled Trial Data.

Author

Claus, Juana, ten Doesschate, Thijs, Taks, Esther, Debisarun, Priya A., Smits, Gaby, van Binnendijk, Rob, van der Klis, Fiona, Verhagen, Lilly M., de Jonge, Marien I., Bonten, Marc J. M., Netea, Mihai G., and van de Wijgert, Janneke H. H. M.

Subjects
MEDICAL personnel, ANTIBODY formation, RANDOMIZED controlled trials, POST-acute COVID-19 syndrome, COVID-19
Abstract

SARS-CoV-2 infections elicit antibodies against the viral spike (S) and nucleocapsid (N) proteins; COVID-19 vaccines against the S-protein only. The BCG-Corona trial, initiated in March 2020 in SARS-CoV-2-naïve Dutch healthcare workers, captured several epidemic peaks and the introduction of COVID-19 vaccines during the one-year follow-up. We assessed determinants of systemic anti-S1 and anti-N immunoglobulin type G (IgG) responses using trial data. Participants were randomised to BCG or placebo vaccination, reported daily symptoms, SARS-CoV-2 test results, and COVID-19 vaccinations, and donated blood for SARS-CoV-2 serology at two time points. In the 970 participants, anti-S1 geometric mean antibody concentrations (GMCs) were much higher than anti-N GMCs. Anti-S1 GMCs significantly increased with increasing number of immune events (SARS-CoV-2 infection or COVID-19 vaccination): 104.7 international units (IU)/mL, 955.0 IU/mL, and 2290.9 IU/mL for one, two, and three immune events, respectively (p < 0.001). In adjusted multivariable linear regression models, anti-S1 and anti-N log10 concentrations were significantly associated with infection severity, and anti-S1 log10 concentration with COVID-19 vaccine type/dose. In univariable models, anti-N log10 concentration was also significantly associated with acute infection duration, and severity and duration of individual symptoms. Antibody concentrations were not associated with long COVID or long-term loss of smell/taste. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Anticoagulant interventions in hospitalized patients with COVID‐19: A scoping review of randomized controlled trials and call for international collaboration

Author

Tritschler, Tobias, Mathieu, Marie‐Eve, Skeith, Leslie, Rodger, Marc, Middeldorp, Saskia, Brighton, Timothy, Sandset, Per Morten, Kahn, Susan R., Angus, Derek C., Blondon, Marc, Bonten, Marc J., Cattaneo, Marco, Cushman, Mary, Derde, Lennie P.G., DeSancho, Maria T., Diehl, Jean‐Luc, Goligher, Ewan, Jilma, Bernd, Jüni, Peter, Lawler, Patrick R., Marietta, Marco, Marshall, John C., McArthur, Colin, Miranda, Carlos Henrique, Mirault, Tristan, Morici, Nuccia, Perepu, Usha, Schörgenhofer, Christian, Sholzberg, Michelle, Spyropoulos, Alex C., Webb, Steve A., Zarychanski, Ryan, Zuily, Stéphane, and Le Gal, Grégoire

Published
2020
Full Text
View/download PDF

24. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)

Author

Paniagua-García, María, primary, Bravo-Ferrer, Jose M., additional, Pérez-Galera, Salvador, additional, Kostyanev, Tomislav, additional, de Kraker, Marlieke E.A., additional, Feifel, Jan, additional, Palacios-Baena, Zaira R., additional, Schotsman, Joost, additional, Cantón, Rafael, additional, Daikos, George L., additional, Carevic, Biljana, additional, Dragovac, Gorana, additional, Tan, Lionel K., additional, Raka, Lul, additional, Hristea, Adriana, additional, Viale, Pierluigi, additional, Akova, Murat, additional, Cano, Ángela, additional, Reguera, Jose María, additional, Bartoloni, Alessandro, additional, Florescu, Simin-Aysel, additional, Benea, Serban, additional, Bukarica, Ljiljana, additional, Asensio, Ángel, additional, Korten, Volkan, additional, Grundmann, Hajo, additional, Goossens, Herman, additional, Bonten, Marc J., additional, Gutiérrez-Gutiérrez, Belén, additional, Rodríguez-Baño, Jesús, additional, Serna, Almudena de la, additional, Monteau, Sophie, additional, Palomo, Virginia, additional, Soriano, Elena, additional, Gutierrez, David, additional, Moreno, Elisa, additional, Sojo-Dorado, Jesus, additional, Morales, Isabel, additional, Maldonado, Natalia, additional, Santis, Lucia Valiente de, additional, Ciezar, Antonio Plata, additional, Ruiz Mesa, Juan Diego, additional, Diaz, Beatriz Sobrino, additional, Gomez, Ignacio Marquez, additional, Camacho, Ines Perez, additional, Cano, Angela, additional, Frutos-Adame, Azahara, additional, Guzman-Puche, Julia, additional, Gracia-Ahufinger, Irene, additional, Perez-Nadales, Elena, additional, Torre-Gimenez, Julian, additional, Pyrpasopoulou, Athina, additional, Iosifidis, Elias, additional, Chorafa, Elsa, additional, Radovanovic, Ivana, additional, Petrovic, Sladjana, additional, Cvetkovi, Slavica, additional, Melentijevic, Srdjan-Sanja, additional, Bicmen, Can, additional, Senol, Gunes, additional, Tubau, Fe, additional, Camara, Jordi, additional, Daniel Gumucio, Victor, additional, Bassoulis, Dimitris, additional, Deliolanis, John, additional, Pitiriga, Vassiliki Ch., additional, Triarides, Nikolaos, additional, Argiti, Efstathia, additional, Legakis, Nikolaos J., additional, Margarita, Kyriakidou, additional, Gijón-Cordero, Desirée, additional, Ruiz-Garbajosa, Patricia, additional, Rossolini, Gian Maria, additional, Nica, Maria, additional, Talapan, Daniela, additional, Medić, Deana, additional, Prijić, Sanja Maričić, additional, Caballero, Mireia Cantero, additional, Ramírez, Lina M Parra, additional, Bilgin, Hüseyin, additional, Dalekos, George N., additional, Stefos, Aggelos, additional, Spyridis, Nikolaos, additional, Michos, Athanasios, additional, De Rosa, Francesco Giuseppe, additional, Cavallo, Rossana, additional, Petrosillo, Nicola, additional, Dicaro, Antonio, additional, Landini, Maria Paola, additional, degli Atti, Marta Luisa Ciofi, additional, Masanovic, Mileva, additional, Matkovic, Dusan, additional, Tsiodras, Sotirios, additional, Blasi, Francesco, additional, pasquale, Marta Di, additional, Viscoli, Claudio, additional, Vata, Andrei, additional, Dorneanu, Olivia, additional, Kapisyzi, Perlat, additional, Vince, Adriana, additional, Tsigou, Evdoxia, additional, Maltezos, Efstratios, additional, Komnos, Apostolos, additional, Gogos, Charalampos, additional, Franzetti, Fabio, additional, Antonelli, Massimo, additional, Lupse, Mihaela, additional, Corneci, Dan, additional, Tomescu, Dana, additional, Georgescu, Anca, additional, Mitrović, Goran, additional, Krstić, Nataša Lukić, additional, Kurti, Arsim, additional, Reuter, Sandra, additional, Díaz-Pollán, Beatriz, additional, Sabater, Julia Origüen, additional, Muñoz, Patricia, additional, Azap, Alpay, additional, ancak, Banu, additional, Sahin, Arife, additional, and Akalin, Halis, additional

Published
2024
Full Text
View/download PDF

30. Corrigendum: The impact of circadian rhythm on Bacillus Calmette-Guérin vaccination effects on SARS-CoV-2 infections

Author

Föhse, Konstantin, primary, Taks, Esther J. M., additional, Moorlag, Simone J. C. F. M., additional, Bonten, Marc J. M., additional, van Crevel, Reinout, additional, ten Oever, Jaap, additional, van Werkhoven, Cornelis H., additional, Netea, Mihai G., additional, van de Maat, Josephine S., additional, and Hoogerwerf, Jacobien J., additional

Published
2023
Full Text
View/download PDF

31. BCG Vaccination of Health Care Workers Does Not Reduce SARS-CoV-2 Infections nor Infection Severity or Duration: a Randomized Placebo-Controlled Trial

Author

Claus, Juana, primary, ten Doesschate, Thijs, additional, Gumbs, Cheyenne, additional, van Werkhoven, Cornelis H., additional, van der Vaart, Thomas W., additional, Janssen, Axel B., additional, Smits, Gaby, additional, van Binnendijk, Rob, additional, van der Klis, Fiona, additional, van Baarle, Debbie, additional, Paganelli, Fernanda L., additional, Leavis, Helen, additional, Verhagen, Lilly M., additional, Joosten, Simone A., additional, Bonten, Marc J. M., additional, Netea, Mihai G., additional, van de Wijgert, Janneke H. H. M., additional, Boersma, Wim G., additional, Bulut, Özlem, additional, van Crevel, Reinout, additional, Debisarun, Priya A., additional, Hoogerwerf, Jacobien, additional, de Jonge, Marien, additional, Kerckhoffs, Angele P. M., additional, Knol, Edward, additional, Koopman, Jan Pieter R., additional, Kuiper, Vincent P., additional, Lalmohamed, Arief, additional, Moorlag, Simone J. C. F. M., additional, Nierkens, Stefan, additional, van Nieuwkoop, Cees, additional, 10 Oever, Jaap, additional, Ottenhoff, Tom H. M., additional, Paternotte, Nienke, additional, Rijnders, Bart J. A., additional, Roukens, Anna H. E., additional, Taks, Esther, additional, Top, Janetta, additional, Veerman, Karin M., additional, Voss, Andreas, additional, and Willems, Rob, additional

Published
2023
Full Text
View/download PDF

32. Cohort profile of PLUTO: a perioperative biobank focusing on prediction and early diagnosis of postoperative complications

Author

de Mul, Nikki, primary, Verlaan, Diede, additional, Ruurda, Jelle P, additional, van Grevenstein, Wilhelmina M U, additional, Hagendoorn, Jeroen, additional, de Borst, Gert-Jan, additional, Vriens, Menno R, additional, de Bree, Remco, additional, Zweemer, Ronald P, additional, Vogely, Charles, additional, Haitsma Mulier, Jelle L G, additional, Vernooij, Lisette M, additional, Reitsma, Johannes B, additional, de Zoete, Marcel R, additional, Top, Janetta, additional, Kluijtmans, Jan A J, additional, Hoefer, Imo E, additional, Noordzij, Peter, additional, Rettig, Thijs, additional, Marsman, Marije, additional, de Smet, Anne Marie G A, additional, Derde, Lennie, additional, van Waes, Judith, additional, Rijsdijk, Mienke, additional, Schellekens, Willem Jan M, additional, Bonten, Marc J M, additional, Slooter, Arjen J C, additional, and Cremer, Olaf L, additional

Published
2023
Full Text
View/download PDF

33. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

Author

Pérez-Galera, Salvador, primary, Bravo-Ferrer, Jose M., additional, Paniagua, María, additional, Kostyanev, Tomislav, additional, de Kraker, Marlieke E.A., additional, Feifel, Jan, additional, Sojo-Dorado, Jesús, additional, Schotsman, Joost, additional, Cantón, Rafael, additional, Daikos, George L., additional, Carevic, Biljana, additional, Dragovac, Gorana, additional, Tan, Lionel K., additional, Raka, Lul, additional, Hristea, Adriana, additional, Viale, Pierluigi, additional, Akova, Murat, additional, Reguera, Jose María, additional, Valiente de Santis, Lucía, additional, Torre-Cisneros, Julián, additional, Cano, Ángela, additional, Roilides, Emmanuel, additional, Radulovic, Lili, additional, Kirakli, Cenk, additional, Shaw, Evelyn, additional, Falagas, Matthew E., additional, Pintado, Vicente, additional, Goossens, Herman, additional, Bonten, Marc J., additional, Gutiérrez-Gutiérrez, Belén, additional, Rodriguez-Baño, Jesús, additional, de la Serna, Almudena, additional, Monteau, Sophie, additional, Palomo, Virginia, additional, Soriano, Elena, additional, Gutierrez, David, additional, Moreno, Elisa, additional, Palacios, Zaira, additional, Morales, Isabel, additional, Maldonado, Natalia, additional, Ciezar, Antonio Plata, additional, Ruiz Mesa, Juan Diego, additional, Diaz, Beatriz Sobrino, additional, Gomez, Ignacio Marquez, additional, Camacho, Ines Perez, additional, Frutos-Adame, Azahara, additional, Guzman-Puche, Julia, additional, Gracia-Ahufinger, Irene, additional, Perez-Nadales, Elena, additional, Torre-Gimenez, Julian, additional, Pyrpasopoulou, Athina, additional, Iosifidis, Elias, additional, Chorafa, Elsa, additional, Radovanovic, Ivana, additional, Petrovic, Sladjana, additional, Cvetkovi, Slavica, additional, Melentijevic, Srdjan-Sanja, additional, Bicmen, Can, additional, Senol, Gunes, additional, Tubau, Fe, additional, Camara, Jordi, additional, Gumucio, Victor Daniel, additional, Bassoulis, Dimitris, additional, Deliolanis, John, additional, Pitiriga, Vassiliki Ch., additional, Triarides, Nikolaos, additional, Argiti, Efstathia, additional, Legakis, Nikolaos J., additional, Margarita, Kyriakidou, additional, Gijón-Cordero, Desirée, additional, Ruiz-Garbajosa, Patricia, additional, Bartoloni, Alessandro, additional, Rossolini, Gian Maria, additional, Florescu, Simin-Aysel, additional, Nica, Maria, additional, Benea, Serban, additional, Talapan, Daniela, additional, Medić, Deana, additional, Prijić, Sanja Maričić, additional, Caballero, Mireia Cantero, additional, Parra Ramírez, Lina M., additional, Korten, Volkan, additional, Bilgin, Hüseyin, additional, Dalekos, George N., additional, Stefos, Aggelos, additional, Spyridis, Nikolaos, additional, Michos, Athanasios, additional, De Rosa, Francesco Giuseppe, additional, Cavallo, Rossana, additional, Petrosillo, Nicola, additional, Dicaro, Antonio, additional, Landini, Maria Paola, additional, Ciofi degli Atti, Marta Luisa, additional, Masanovic, Mileva, additional, Matkovic, Dusan, additional, Tsiodras, Sotirios, additional, Blasi, Francesco, additional, Di pasquale, Marta, additional, Viscoli, Claudio, additional, Vata, Andrei, additional, Dorneanu, Olivia, additional, Kapisyzi, Perlat, additional, Vince, Adriana, additional, Tsigou, Evdoxia, additional, Maltezos, Efstratios, additional, Komnos, Apostolos, additional, Gogos, Charalampos, additional, Franzetti, Fabio, additional, Antonelli, Massimo, additional, Lupse, Mihaela, additional, Corneci, Dan, additional, Tomescu, Dana, additional, Georgescu, Anca, additional, Bukarica, Ljiljana, additional, Mitrović, Goran, additional, Krstić, Nataša Lukić, additional, Kurti, Arsim, additional, Díaz-Pollán, Beatriz, additional, Sabater, Julia Origüen, additional, Muñoz, Patricia, additional, Azap, Alpay, additional, Sancak, Banu, additional, Sahin, Arife, additional, and Akalin, Halis, additional

Published
2023
Full Text
View/download PDF

34. Longitudinal Study of Dynamic Epidemiology of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Pigs and Humans Living and/or Working on Pig Farms

Author

Dohmen, Wietske, Liakopoulos, Apostolos, Bonten, Marc J M, Mevius, Dik J, Heederik, Dick J J, Dohmen, Wietske, Liakopoulos, Apostolos, Bonten, Marc J M, Mevius, Dik J, and Heederik, Dick J J

Abstract

Extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales have been increasingly isolated from pigs, highlighting their potential for transmission to humans living and/or working within pig farms. As longitudinal data on the prevalence and the molecular characteristics of such isolates from the high-risk farming population remain scarce, we performed a long-term study on 39 Dutch pig farms. Fecal samples from pigs, farmers, family members, and employees were collected during four sampling occasions with a 6-month period. The presence of ESBL-producing Enterobacterales and their molecular characteristics (ESBL gene, plasmid, and sequence types) were determined by standard methods. Data on personal and farm characteristics were collected using questionnaires. ESBL-producing Escherichia coli was present in pigs at least once for 18 of 39 farms and in 17 of 146 farmers, family members, and/or employees. Among these 417 E. coli isolates, bla CTX-M-1 was the most frequently observed ESBL gene in pigs ( n = 261) and humans ( n = 25). Despite the great variety in plasmid (sub)types and E. coli sequence types (STs), we observed genetic similarity between human- and pig-derived isolates in (i) ESBL gene, plasmid (sub)type, and ST, suggesting potential clonal transmission in seven farms, and (ii) only ESBL gene and plasmid (sub)type, highlighting the possibility of horizontal transfer in four farms. Five pig farmers carried ESBL producers repeatedly, of whom two carried an identical combination of gene, plasmid (sub)type, and ST over time. Human ESBL carriage was associated with both presence of ESBL producers in pigs and average number of hours working on the pig farm per week, while prolonged human carriage was observed only incidentally. IMPORTANCE Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli represents a public health hazard due to reduced therapeutic options for the treatment of infections. Although direct contact with pigs is considere

Published
2023

35. Longitudinal Study of Dynamic Epidemiology of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Pigs and Humans Living and/or Working on Pig Farms

Author

IRAS OH Epidemiology Microbial Agents, Klinische infectiologie en microb. lab., Faculteit Diergeneeskunde, Dohmen, Wietske, Liakopoulos, Apostolos, Bonten, Marc J M, Mevius, Dik J, Heederik, Dick J J, IRAS OH Epidemiology Microbial Agents, Klinische infectiologie en microb. lab., Faculteit Diergeneeskunde, Dohmen, Wietske, Liakopoulos, Apostolos, Bonten, Marc J M, Mevius, Dik J, and Heederik, Dick J J

Published
2023

36. The impact of Bacillus Calmette-Guérin vaccination on antibody response after COVID-19 vaccination

Author

Epi Infectieziekten Team 1, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, Epi Infectieziekten Team 1b, Taks, Esther J M, Moorlag, Simone J C F M, Föhse, Konstantin, Simonetti, Elles, van der Gaast-de Jongh, Christa E, van Werkhoven, Cornelis H, Bonten, Marc J M, Oever, Jaap Ten, de Jonge, Marien I, van de Wijgert, Janneke H H M, Netea, Mihai G, Epi Infectieziekten Team 1, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, Epi Infectieziekten Team 1b, Taks, Esther J M, Moorlag, Simone J C F M, Föhse, Konstantin, Simonetti, Elles, van der Gaast-de Jongh, Christa E, van Werkhoven, Cornelis H, Bonten, Marc J M, Oever, Jaap Ten, de Jonge, Marien I, van de Wijgert, Janneke H H M, and Netea, Mihai G

Published
2023

37. Corrigendum: The impact of circadian rhythm on Bacillus Calmette-Guérin vaccination effects on SARS-CoV-2 infections (Front. Immunol., (2023), 14, 980711, 10.3389/fimmu.2023.980711)

Author

Epi Infectieziekten, Infection & Immunity, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, Epi Infectieziekten Team 1, Föhse, Konstantin, Taks, Esther J M, Moorlag, Simone J C F M, Bonten, Marc J M, van Crevel, Reinout, Ten Oever, Jaap, van Werkhoven, Cornelis H, Netea, Mihai G, van de Maat, Josephine S, Hoogerwerf, Jacobien J, Epi Infectieziekten, Infection & Immunity, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, Epi Infectieziekten Team 1, Föhse, Konstantin, Taks, Esther J M, Moorlag, Simone J C F M, Bonten, Marc J M, van Crevel, Reinout, Ten Oever, Jaap, van Werkhoven, Cornelis H, Netea, Mihai G, van de Maat, Josephine S, and Hoogerwerf, Jacobien J

Published
2023

38. The impact of circadian rhythm on Bacillus Calmette-Guérin vaccination effects on SARS-CoV-2 infections

Author

Epi Infectieziekten, Infection & Immunity, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, Epi Infectieziekten Team 1, Föhse, Konstantin, Taks, Esther J M, Moorlag, Simone J C F M, Bonten, Marc J M, van Crevel, Reinout, Ten Oever, Jaap, van Werkhoven, Cornelis H, Netea, Mihai G, van de Maat, Josephine S, Hoogerwerf, Jacobien J, Epi Infectieziekten, Infection & Immunity, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, Epi Infectieziekten Team 1, Föhse, Konstantin, Taks, Esther J M, Moorlag, Simone J C F M, Bonten, Marc J M, van Crevel, Reinout, Ten Oever, Jaap, van Werkhoven, Cornelis H, Netea, Mihai G, van de Maat, Josephine S, and Hoogerwerf, Jacobien J

Published
2023

39. Cohort profile of PLUTO: a perioperative biobank focusing on prediction and early diagnosis of postoperative complications

Author

AIOS Anesthesiologie, Epi Infectieziekten Team 1, Infection & Immunity, MS CGO, Cancer, Zorgeenheid Vaatchirurgie Medisch, Circulatory Health, Regenerative Medicine and Stem Cells, Heelkunde Opleiding, MS Hoofd-Hals Chirurgische Oncologie, MS Gynaecologische Oncologie, MS Orthopaedie Algemeen, Onderzoek, Epi Methoden Team 4, JC onderzoeksprogramma Methodology, MMB Research line 2, Medische Microbiologie, JC onderzoeksprogramma Infectious Diseases, Centraal Diagnostisch Laboratorium, Medische staf Anesthesiologie, DVF Medisch, Medische Staf Intensive Care, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, AIOS Psychiatrie, Brain, de Mul, Nikki, Verlaan, Diede, Ruurda, Jelle P, van Grevenstein, Wilhelmina M U, Hagendoorn, Jeroen, de Borst, Gert-Jan, Vriens, Menno R, de Bree, Remco, Zweemer, Ronald P, Vogely, Charles, Haitsma Mulier, Jelle L G, Vernooij, Lisette M, Reitsma, Johannes B, de Zoete, Marcel R, Top, Janetta, Kluijtmans, Jan A J, Hoefer, Imo E, Noordzij, Peter, Rettig, Thijs, Marsman, Marije, de Smet, Anne Marie G A, Derde, Lennie, van Waes, Judith, Rijsdijk, Mienke, Schellekens, Willem Jan M, Bonten, Marc J M, Slooter, Arjen J C, Cremer, Olaf L, AIOS Anesthesiologie, Epi Infectieziekten Team 1, Infection & Immunity, MS CGO, Cancer, Zorgeenheid Vaatchirurgie Medisch, Circulatory Health, Regenerative Medicine and Stem Cells, Heelkunde Opleiding, MS Hoofd-Hals Chirurgische Oncologie, MS Gynaecologische Oncologie, MS Orthopaedie Algemeen, Onderzoek, Epi Methoden Team 4, JC onderzoeksprogramma Methodology, MMB Research line 2, Medische Microbiologie, JC onderzoeksprogramma Infectious Diseases, Centraal Diagnostisch Laboratorium, Medische staf Anesthesiologie, DVF Medisch, Medische Staf Intensive Care, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, AIOS Psychiatrie, Brain, de Mul, Nikki, Verlaan, Diede, Ruurda, Jelle P, van Grevenstein, Wilhelmina M U, Hagendoorn, Jeroen, de Borst, Gert-Jan, Vriens, Menno R, de Bree, Remco, Zweemer, Ronald P, Vogely, Charles, Haitsma Mulier, Jelle L G, Vernooij, Lisette M, Reitsma, Johannes B, de Zoete, Marcel R, Top, Janetta, Kluijtmans, Jan A J, Hoefer, Imo E, Noordzij, Peter, Rettig, Thijs, Marsman, Marije, de Smet, Anne Marie G A, Derde, Lennie, van Waes, Judith, Rijsdijk, Mienke, Schellekens, Willem Jan M, Bonten, Marc J M, Slooter, Arjen J C, and Cremer, Olaf L

Published
2023

40. Value of diagnosing immunological phenomena in patients with suspected endocarditis

Author

Infection & Immunity, Epi Infectieziekten Team 1, JC onderzoeksprogramma Infectieziekten, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, van der Vaart, Thomas W, Heerschop, Luca L, Bouma, Berto J, Freudenburg, Wieke, Bonten, Marc J M, Prins, Jan M, van der Meer, Jan T M, Infection & Immunity, Epi Infectieziekten Team 1, JC onderzoeksprogramma Infectieziekten, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, van der Vaart, Thomas W, Heerschop, Luca L, Bouma, Berto J, Freudenburg, Wieke, Bonten, Marc J M, Prins, Jan M, and van der Meer, Jan T M

Published
2023

41. Erratum: Semiautomated surveillance of deep surgical site infections after colorectal surgeries: A multicenter external validation of two surveillance algorithms (Infection Control & Hospital Epidemiology (2023) 44: 4 (616-623) DOI: 10.1017/ice.2022.147)

Author

MMB Onderzoek en Onderwijs, MMB, MMB opleiding Arts microbioloog, Epi Infectieziekten, Infection & Immunity, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, MMB Medische Staf, Verberk, Janneke D M, van der Kooi, Tjallie I I, Hetem, David J, Oostdam, Nicolette E W M, Noordergraaf, Mieke, de Greeff, Sabine C, Bonten, Marc J M, van Mourik, Maaike S M, MMB Onderzoek en Onderwijs, MMB, MMB opleiding Arts microbioloog, Epi Infectieziekten, Infection & Immunity, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, MMB Medische Staf, Verberk, Janneke D M, van der Kooi, Tjallie I I, Hetem, David J, Oostdam, Nicolette E W M, Noordergraaf, Mieke, de Greeff, Sabine C, Bonten, Marc J M, and van Mourik, Maaike S M

Published
2023

42. Positive impact of [18F]FDG-PET/CT on mortality in patients with Staphylococcus aureus bacteremia explained by immortal time bias

Author

Infection & Immunity, Epi Infectieziekten Team 1, JC onderzoeksprogramma Infectious Diseases, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, van der Vaart, Thomas W, Prins, Jan M, van Werkhoven, Cornelis H, Ten Doesschate, Thijs, Soetekouw, Robin, van Twillert, Gitte, Veenstra, Jan, Herpers, Bjorn L, Rozemeijer, Wouter, Jansen, Rogier R, Bonten, Marc J M, van der Meer, Jan T M, Infection & Immunity, Epi Infectieziekten Team 1, JC onderzoeksprogramma Infectious Diseases, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, van der Vaart, Thomas W, Prins, Jan M, van Werkhoven, Cornelis H, Ten Doesschate, Thijs, Soetekouw, Robin, van Twillert, Gitte, Veenstra, Jan, Herpers, Bjorn L, Rozemeijer, Wouter, Jansen, Rogier R, Bonten, Marc J M, and van der Meer, Jan T M

Published
2023

43. Semiautomated surveillance of deep surgical site infections after colorectal surgeries: A multicenter external validation of two surveillance algorithms

Author

MMB Onderzoek en Onderwijs, MMB, MMB opleiding Arts microbioloog, Epi Infectieziekten, Infection & Immunity, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, MMB Medische Staf, Verberk, Janneke D M, van der Kooi, Tjallie I I, Hetem, David J, Oostdam, Nicolette E W M, Noordergraaf, Mieke, de Greeff, Sabine C, Bonten, Marc J M, van Mourik, Maaike S M, MMB Onderzoek en Onderwijs, MMB, MMB opleiding Arts microbioloog, Epi Infectieziekten, Infection & Immunity, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, MMB Medische Staf, Verberk, Janneke D M, van der Kooi, Tjallie I I, Hetem, David J, Oostdam, Nicolette E W M, Noordergraaf, Mieke, de Greeff, Sabine C, Bonten, Marc J M, and van Mourik, Maaike S M

Published
2023

44. Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study

Author

Epi Infectieziekten, Infection & Immunity, Epi Infectieziekten Team 1, Immuno/reuma patientenzorg, Child Health, JC onderzoeksprogramma Methodologie, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, CTI Bont, Infectieziekten onderzoek1 (Bont), Epi Infectieziekten Team 2, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, van Boven, Michiel, van Dorp, Christiaan H, Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A, Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J, Kretzschmar, Mirjam E, Bruijning-Verhagen, Patricia, Epi Infectieziekten, Infection & Immunity, Epi Infectieziekten Team 1, Immuno/reuma patientenzorg, Child Health, JC onderzoeksprogramma Methodologie, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, CTI Bont, Infectieziekten onderzoek1 (Bont), Epi Infectieziekten Team 2, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, van Boven, Michiel, van Dorp, Christiaan H, Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A, Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J, Kretzschmar, Mirjam E, and Bruijning-Verhagen, Patricia

Published
2023

46. BCG Vaccination of Health Care Workers Does Not Reduce SARS-CoV-2 Infections nor Infection Severity or Duration: a Randomized Placebo-Controlled Trial

Author

Claus, Juana, Ten Doesschate, Thijs, Gumbs, Cheyenne, van Werkhoven, Cornelis H, van der Vaart, Thomas W, Janssen, Axel B, Smits, Gaby, van Binnendijk, Rob, van der Klis, Fiona, van Baarle, Debbie, Paganelli, Fernanda L, Leavis, Helen, Verhagen, Lilly M, Joosten, Simone A, Bonten, Marc J M, Netea, Mihai G, and van de Wijgert, Janneke H H M

Subjects
randomized placebo-controlled clinical trial, Bacillus Calmette-Guerin vaccine, SARS-CoV-2, COVID-19, health care workers
Abstract

Bacillus Calmette-Guerin (BCG) vaccination has been hypothesized to reduce severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, severity, and/or duration via trained immunity induction. Health care workers (HCWs) in nine Dutch hospitals were randomized to BCG or placebo vaccination (1:1) in March and April 2020 and followed for 1 year. They reported daily symptoms, SARS-CoV-2 test results, and health care-seeking behavior via a smartphone application, and they donated blood for SARS-CoV-2 serology at two time points. A total of 1,511 HCWs were randomized and 1,309 analyzed (665 BCG and 644 placebo). Of the 298 infections detected during the trial, 74 were detected by serology only. The SARS-CoV-2 incidence rates were 0.25 and 0.26 per person-year in the BCG and placebo groups, respectively (incidence rate ratio, 0.95; 95% confidence interval, 0.76 to 1.21; P = 0.732). Only three participants required hospitalization for SARS-CoV-2. The proportions of participants with asymptomatic, mild, or moderate infections and the mean infection durations did not differ between randomization groups. In addition, unadjusted and adjusted logistic regression and Cox proportional hazards models showed no differences between BCG and placebo vaccination for any of these outcomes. The percentage of participants with seroconversion (7.8% versus 2.8%; P = 0.006) and mean SARS-CoV-2 anti-S1 antibody concentration (13.1 versus 4.3 IU/mL; P = 0.023) were higher in the BCG than placebo group at 3 months but not at 6 or 12 months postvaccination. BCG vaccination of HCWs did not reduce SARS-CoV-2 infections nor infection duration or severity (ranging from asymptomatic to moderate). In the first 3 months after vaccination, BCG vaccination may enhance SARS-CoV-2 antibody production during SARS-CoV-2 infection. IMPORTANCE While several BCG trials in adults were conducted during the 2019 coronavirus disease epidemic, our data set is the most comprehensive to date, because we included serologically confirmed infections in addition to self-reported positive SARS-CoV-2 test results. We also collected data on symptoms for every day during the 1-year follow-up period, which enabled us to characterize infections in detail. We found that BCG vaccination did not reduce SARS-CoV-2 infections nor infection duration or severity but may have enhanced SARS-CoV-2 antibody production during SARS-CoV-2 infection in the first 3 months after vaccination. These results are in agreement with other BCG trials that reported negative results (but did not use serological endpoints), except for two trials in Greece and India that reported positive results but had few endpoints and included endpoints that were not laboratory confirmed. The enhanced antibody production is in agreement with prior mechanistic studies but did not translate into protection from SARS-CoV-2 infection.

Published
2023

47. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19

Author

Bradbury, Charlotte A., Lawler, Patrick R., Stanworth, Simon J., McVerry, Bryan J., McQuilten, Zoe, Higgins, Alisa M., Mouncey, Paul R., Al-Beidh, Farah, Rowan, Kathryn M., Berry, Lindsay R., Lorenzi, Elizabeth, Zarychanski, Ryan, Arabi, Yaseen M., Annane, Djillali, Beane, Abi, Van Bentum-Puijk, Wilma, Bhimani, Zahra, Bihari, Shailesh, Bonten, Marc J. M., Brunkhorst, Frank M., Buzgau, Adrian, Buxton, Meredith, Carrier, Marc, Cheng, Allen C., Cove, Matthew, Detry, Michelle A., Estcourt, Lise J., Fitzgerald, Mark, Girard, Timothy D., Goligher, Ewan C., Goossens, Herman, Haniffa, Rashan, Hills, Thomas, Huang, David T., Horvat, Christopher M., Hunt, Beverley J., Ichihara, Nao, Lamontagne, Francois, Leavis, Helen L., Linstrum, Kelsey M., Litton, Edward, Marshall, John C., McAuley, Daniel F., McGlothlin, Anna, McGuinness, Shay P., Middeldorp, Saskia, Montgomery, Stephanie K., Morpeth, Susan C., Murthy, Srinivas, Neal, Matthew D., Nichol, Alistair D., Parke, Rachael L., Parker, Jane C., Reyes, Luis, Saito, Hiroki, Santos, Marlene S., Saunders, Christina T., Serpa-Neto, Ary, Seymour, Christopher W., Shankar-Hari, Manu, Singh, Vanessa, Tolppa, Timo, Turgeon, Alexis F., Turner, Anne M., van de Veerdonk, Frank L., Green, Cameron, Lewis, Roger J., Angus, Derek C., McArthur, Colin J., Berry, Scott, Derde, Lennie P. G., Webb, Steve A., Gordon, Anthony C., Depuydt, Pieter, De Waele, Jan, De Bus, Liesbet, Fierens, Jan, Vermassen, Joris, REMAP-CAP Investigators, University of Bristol [Bristol], University Health Network, University of Toronto, University of Oxford, University of Pittsburgh (PITT), Pennsylvania Commonwealth System of Higher Education (PCSHE), Monash University [Melbourne], Imperial College London, University of Manitoba [Winnipeg], Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), University Medical Center [Utrecht], St. Michael's Hospital, 215522, CS-2016-16-011, RP-2015-06-18, National Institutes of Health, NIH, U.S. Department of Defense, DOD, National Institute of General Medical Sciences, NIGMS, National Institute of Neurological Disorders and Stroke, NINDS, Gordon and Betty Moore Foundation, GBMF, Medtronic, Baxter International, Medical Center, University of Pittsburgh, CancerCare Manitoba Foundation, CCMF, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NICHD, Wellcome Trust, WT, Health Research Board, HRB: CTN 2014-012, Horizon 2020 Framework Programme, H2020: 101003589, LAM Therapeutics, Canadian Institutes of Health Research, IRSC: 158584, Medical Research Council, MRC, National Institute for Health and Care Research, NIHR, European Commission, EC, National Heart and Lung Institute, NHLI, Queen's University Belfast, QUB: US8962032, National Health and Medical Research Council, NHMRC: APP1101719, National Medical Research Council, NMRC, Health Research Council of New Zealand, HRC: 16/631, Ministère des Affaires Sociales et de la Santé: PHRC-20-0147, Innovate UK, Horizon 2020, Pharmaceuticals Bayer, Swedish Orphan Biovitrum, NIHR Imperial Biomedical Research Centre, BRC, Minderoo Foundation, Funding/Support: This study was funded by the following: the Platform for European Preparedness Against (Re-)Emerging Epidemics (PREPARE) consortium of the European Union, FP7-HEALTH-2013-INNOVATION-1 (grant 602525), the Rapid European COVID-19 Emergency Research Response (RECOVER) consortium of the European Union’s Horizon 2020 Research and Innovation Programme (grant 101003589), the Australian National Health and Medical Research Council (grant APP1101719), the Health Research Council of New Zealand (grant 16/631), the Canadian Institute of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program (grant 158584), the NIHR and the NIHR Imperial Biomedical Research Centre, the Health Research Board of Ireland (grant CTN 2014-012), the University of Pittsburgh Medical Center (UPMC) Learning While Doing Program, the Translational Breast Cancer Research Consortium, the French Ministry of Health (grant PHRC-20-0147), the Minderoo Foundation, and the Wellcome Trust Innovations Project (grant 215522). Dr Shankar-Hari is funded by an NIHR clinician scientist fellowship (grant CS-2016-16-011) and Dr Gordon is funded by an NIHR research professorship (grant RP-2015-06-18)., The REMAP-CAP platform is supported by the Australian and New Zealand Intensive Care Society Clinical Trials Group, the Canadian Critical Care Clinical Trials Group, the Irish Critical Care Clinical Trials Network, the UK Critical Care Research Group and the International Forum of Acute Care Trialists., REMAP-CAP was supported in the Netherlands by the Research Collaboration Critical Care the Netherlands, reported receipt of personal fees from Lilly, BMS-Pfizer, Bayer, Amgen, Novartis, Janssen, Portola, Ablynx, and Grifols. Dr Lawler reported receipt of personal fees from Novartis, CorEvitas, and Brigham and Women’s Hospital and royalties from McGraw-Hill Publishing. Dr McVerry reported receipt of grants from the National Heart, Lung, and Blood Institute and Bayer Pharmaceuticals and personal fees from Boehringer Ingelheim. Dr L. Berry reported being an employee of Berry Consultants, Berry Consultants receives payments for the statistical analysis and design of REMAP-CAP. Dr Lorenzi reported being an employee of Berry Consultants, Berry Consultants receives payments for the statistical analysis and design of REMAP-CAP. Dr Zarychanski reported receipt of grants from the Canadian Institutes of Health Research, LifeArc, Research Manitoba, the CancerCare Manitoba Foundation, Peter Munk Cardiac Centre, and the Thistledown Foundation and research operating support as the Lyonel G. Israels Research Chair in Hematology. Dr Bonten reported membership in international study steering committees, advisory boards, and independent data safety and monitoring committees funded by Janssen Vaccines, Merck Sharp & Dohme, AstraZeneca, Pfizer, and Sanofi Pasteur (all reimbursements to UMC Utrecht). Dr Brunkhorst reported receipt of grants from Jena University Hospital. Dr Buxton reported receipt of a gift from the Breast Cancer Research Foundation and contracts with Amgen and Eisai. Dr Carrier reported receipt of grants from BMS-Pfizer and personal fees from Bayer, Sanofi, Servier, Leo Phama, and BMS-Pfizer to his institution. Dr Cove reported receipt of grants from the National Medical Research Council and personal fees from Baxter and Medtronic. Dr Estcourt reported receipt of grants from the UK National Institute for Health Research (NIHR) and the European Union Horizon 2020 Research and Innovation Programme. Dr Haniffa reported receipt of grants from the UK Research and Innovation/Medical Research Council African Critical Care Registry Network. Dr Horvat reported receipt of grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Neurological Disorders and Stroke. Dr Ichihara reported being affiliated with the Department of Healthcare Quality Assessment, University of Tokyo, which is a social collaboration supported by the National Clinical Database, Johnson & Johnson, and Nipro Corporation. Dr Marshall reported receipt of personal fees from AM Pharma and Critical Care Medicine. Dr McAuley reported receipt of personal fees from Bayer, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Lilly, Vir Biotechnology, Faron Pharmaceutical, and SOBI and grants from the NIHR, the Wellcome Trust, Innovate UK, the UK Medical Research Council, and the Northern Ireland Health and Social Care Research and Development Division, in addition, Dr McAuley had a Queen’s University Belfast patent for novel treatment for inflammatory disease (US8962032), was co-director of research at the Intensive Care Society until June 2021, and was director of the Efficacy and Mechanisms Evaluation Program for the UK Medical Research Council/NIHR. Dr Middeldorp reported receipt of personal fees from Daiichi Sankyo, Bayer, Pfizer, Boehringer Ingelheim, Portola/Alexion, AbbVie, BMS-Pfizer, Sanofi, and Viatris, all paid to his institution, and grants from Daiichi Sankyo, Bayer, Pfizer, and Boehringer Ingelheim. Dr Neal reported equity in Haima Therapeutics, receipt of personal fees from Janssen Pharma and Haemonetics, and receipt of grants from Instrumentation Laboratory, the National Institutes of Health, and the Department of Defense. Dr Nichol reported receipt of personal fees from AM Pharma, paid to his university, and grants from Baxter. Dr Parke reported receipt of grants from Fisher and Paykel Healthcare NZ. Dr Serpa-Neto reported receipt of personal fees from Drager and Endpoint Health. Dr Seymour reported receipt of grants from the Gordon and Betty Moore Foundation and the National Institutes of Health/National Institute of General Medical Sciences. Dr Lewis reported being senior medical scientist at Berry Consultants, Berry Consultants receives payments for the statistical analysis and design of REMAP-CAP. Dr S. Berry reported being an employee with an ownership role at Berry Consultants, Berry Consultants receives payments for the statistical analysis and design of REMAP-CAP. Dr Derde reported being a coordinating committee member for the European Clinical Research Alliance on Infectious Diseases, a member of the Dutch Intensivists Task Force on Acute Infectious Threats, a member of the International Scientific Advisory Board for Sepsis Canada, and a member of the Dutch Academy of Sciences’ Pandemic Preparedness Plan committee. Dr Gordon reported receipt of personal fees from 30 Respiratory, paid to his institution. No other disclosures were reported., European Project: 101003589, H2020-SC1-PHE-CORONAVIRUS-2020,RECOVER(2020), European Project: 602525,EC:FP7:HEALTH,FP7-HEALTH-2013-INNOVATION-1,PREPARE(2014), Investigators, REMAP-CAP Writing Committee for the REMAP-CAP, Vascular Medicine, ACS - Pulmonary hypertension & thrombosis, ARD - Amsterdam Reproduction and Development, and Intensive Care Medicine

Subjects
Adult, Male, Platelet Aggregation Inhibitors/adverse effects, Critical Illness, [SDV]Life Sciences [q-bio], Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], Hemorrhage, Aspirin/adverse effects, Hemorrhage/chemically induced, INFECTION, Humans, COAGULOPATHY, Aspirin, Anticoagulants, COVID-19, Bayes Theorem, Venous Thromboembolism, General Medicine, Middle Aged, Respiration, Artificial, COVID-19 Drug Treatment, Critical Illness/mortality, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Purinergic P2Y Receptor Antagonists/adverse effects, Purinergic P2Y Receptor Antagonists, COVID-19/complications, Female, Human medicine, Anticoagulants/adverse effects, Platelet Aggregation Inhibitors, Venous Thromboembolism/drug therapy
Abstract

Contains fulltext : 248713.pdf (Publisher’s version ) (Closed access) IMPORTANCE: The efficacy of antiplatelet therapy in critically ill patients with COVID-19 is uncertain. OBJECTIVE: To determine whether antiplatelet therapy improves outcomes for critically ill adults with COVID-19. DESIGN, SETTING, AND PARTICIPANTS: In an ongoing adaptive platform trial (REMAP-CAP) testing multiple interventions within multiple therapeutic domains, 1557 critically ill adult patients with COVID-19 were enrolled between October 30, 2020, and June 23, 2021, from 105 sites in 8 countries and followed up for 90 days (final follow-up date: July 26, 2021). INTERVENTIONS: Patients were randomized to receive either open-label aspirin (n = 565), a P2Y12 inhibitor (n = 455), or no antiplatelet therapy (control; n = 529). Interventions were continued in the hospital for a maximum of 14 days and were in addition to anticoagulation thromboprophylaxis. MAIN OUTCOMES AND MEASURES: The primary end point was organ support-free days (days alive and free of intensive care unit-based respiratory or cardiovascular organ support) within 21 days, ranging from -1 for any death in hospital (censored at 90 days) to 22 for survivors with no organ support. There were 13 secondary outcomes, including survival to discharge and major bleeding to 14 days. The primary analysis was a bayesian cumulative logistic model. An odds ratio (OR) greater than 1 represented improved survival, more organ support-free days, or both. Efficacy was defined as greater than 99% posterior probability of an OR greater than 1. Futility was defined as greater than 95% posterior probability of an OR less than 1.2 vs control. Intervention equivalence was defined as greater than 90% probability that the OR (compared with each other) was between 1/1.2 and 1.2 for 2 noncontrol interventions. RESULTS: The aspirin and P2Y12 inhibitor groups met the predefined criteria for equivalence at an adaptive analysis and were statistically pooled for further analysis. Enrollment was discontinued after the prespecified criterion for futility was met for the pooled antiplatelet group compared with control. Among the 1557 critically ill patients randomized, 8 patients withdrew consent and 1549 completed the trial (median age, 57 years; 521 [33.6%] female). The median for organ support-free days was 7 (IQR, -1 to 16) in both the antiplatelet and control groups (median-adjusted OR, 1.02 [95% credible interval {CrI}, 0.86-1.23]; 95.7% posterior probability of futility). The proportions of patients surviving to hospital discharge were 71.5% (723/1011) and 67.9% (354/521) in the antiplatelet and control groups, respectively (median-adjusted OR, 1.27 [95% CrI, 0.99-1.62]; adjusted absolute difference, 5% [95% CrI, -0.2% to 9.5%]; 97% posterior probability of efficacy). Among survivors, the median for organ support-free days was 14 in both groups. Major bleeding occurred in 2.1% and 0.4% of patients in the antiplatelet and control groups (adjusted OR, 2.97 [95% CrI, 1.23-8.28]; adjusted absolute risk increase, 0.8% [95% CrI, 0.1%-2.7%]; 99.4% probability of harm). CONCLUSIONS AND RELEVANCE: Among critically ill patients with COVID-19, treatment with an antiplatelet agent, compared with no antiplatelet agent, had a low likelihood of providing improvement in the number of organ support-free days within 21 days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02735707.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results